Universität zu Köln

Ataseven, Beyhan, Tripon, Denise, Schwameis, Richard, Harter, Philipp, Rhiem, Kerstin, Schneider, Stephanie, Heikaus, Sebastian, Baert, Thais, Francesco, Alesina Pier, Heitz, Florian, Traut, Alexander, Groeben, Harald-Thomas, Schmutzler, Rita and du Bois, Andreas (2021). Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation-real life data. Gynecol. Oncol., 163 (3). S. 569 - 578. SAN DIEGO: ACADEMIC PRESS INC ELSEVIER SCIENCE. ISSN 1095-6859

Full text not available from this repository.

Abstract

Background. We evaluated the clinical impact of germline (g)BRCA1/2-mutation on initial disease presentation, surgical implications, surgical morbidity and survival in patients with advanced epithelial ovarian cancer (EOC) undergoing debulking surgery (DS). Methods. Data of all consecutive EOC patients with stage III/IV, high-grade serous disease and known gBRCA1/ 2 status (gBRCA; non-gBRCA), who underwent DS at our department between 01/2011 and 06/2019 were analyzed. Associations between gBRCA-status and severe postoperative complications and survival were analyzed. Results. gBRCA-status was determined in 50.1% (612/1221) of all patients. gBRCA was present in 21.9% (134/ 612). Significant differences were observed in terms of median age (p = 0.001) and histology (high-grade serous histology gBRCA: 98.5%, non-gBRCA 76.2%; p < 0.001). gBRCA-status had no impact on intraoperative disease presentation, surgical complexity or complete resection rate (gBRCA: 74.4%, non-gBRCA: 69.0%; p = 0.274). gBRCA-status was not predictive for severe postoperative complication (gBRCA: 12.0%, non-gBRCA: 19.1%; p = 0.082). Median PFS and OS was 31/22 and 71/53 months in patients with/without gBRCA-mutation, respectively. gBRCA was a significant prognostic factor for PFS (HR 0.57 p < 0.001) and for OS (HR 0.64, p = 0.048) after adjusting for established prognostic factors. Conclusions. gBRCA-status had no impact on initial disease presentation, surgical results or postoperative complications. gBRCA patients have a significantly longer PFS but the impact on the long term prognosis is unclear. Complete resection remains the most important prognostic factor in patients with EOC independent of gBRCA-status. (c) 2021 Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Ataseven, Beyhan UNSPECIFIED UNSPECIFIED UNSPECIFIED Tripon, Denise UNSPECIFIED UNSPECIFIED UNSPECIFIED Schwameis, Richard UNSPECIFIED UNSPECIFIED UNSPECIFIED Harter, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Rhiem, Kerstin UNSPECIFIED UNSPECIFIED UNSPECIFIED Schneider, Stephanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Heikaus, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Baert, Thais UNSPECIFIED UNSPECIFIED UNSPECIFIED Francesco, Alesina Pier UNSPECIFIED UNSPECIFIED UNSPECIFIED Heitz, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Traut, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Groeben, Harald-Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmutzler, Rita UNSPECIFIED UNSPECIFIED UNSPECIFIED du Bois, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-596427
DOI:	10.1016/j.ygyno.2021.09.004
Journal or Publication Title:	Gynecol. Oncol.
Volume:	163
Number:	3
Page Range:	S. 569 - 578
Date:	2021
Publisher:	ACADEMIC PRESS INC ELSEVIER SCIENCE
Place of Publication:	SAN DIEGO
ISSN:	1095-6859
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language BRCA2 MUTATIONS; 10-YEAR SURVIVAL; FALLOPIAN-TUBE; CLASSIFICATION; ASSOCIATION; BREAST; TRIALS; WOMEN; INDEX; RISK Multiple languages Oncology; Obstetrics & Gynecology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59642